What Is TB-500? A Complete 2026 Guide to the Peptide

TB-500 is a lab-made peptide based on a small active piece of thymosin beta-4, a natural protein your body makes for tissue repair. Researchers study it for cell migration, blood-vessel growth, and recovery after strain or injury, working through the actin that cells use to move toward a damaged area. TB-500 is not FDA-approved, and its compounding status is under active FDA review in 2026.

What is TB-500?

TB-500 is a synthetic peptide. It copies a short, active piece of a natural protein called thymosin beta-4 (often written Tb4). Your body already makes thymosin beta-4 in many tissues, including skin, muscle, and the heart, where it helps cells move and repair after damage.

The full protein has 43 amino acids. TB-500 is a much smaller fragment built around the part that binds actin, a building-block protein inside cells. That fragment is often written as the sequence Ac-LKKTETQ. Because it is smaller and lab-made, it is easier to produce and study than the whole protein.

People search for TB-500 alongside what is tb-500, the thymosin beta-4 fragment, and how it compares to BPC-157. This page covers what it is, how it works, and where it stands with regulators in 2026.

How does TB-500 work?

TB-500 is thought to work by managing actin, the protein cells use to change shape and move. By holding actin monomers ready, it may help cells migrate to a damaged area faster, which is an early step in repair. Researchers also study it for growing new blood vessels and calming inflammation.

• Actin binding: it sequesters actin monomers, keeping them ready for cells to build and move.
• Cell migration: repair cells reach the injured site, an early step in wound closing.
• Angiogenesis: it is studied for new blood-vessel growth, which feeds healing tissue.
• Inflammation: early research looks at whether it helps calm the inflammatory response.

Unlike a peptide that acts mainly at one spot, TB-500 is studied as a more body-wide signal. That is one reason it is often compared with the more localized BPC-157.

How does TB-500 relate to thymosin beta-4?

TB-500 and thymosin beta-4 are related but not the same. Thymosin beta-4 is the full natural 43-amino-acid protein. TB-500 is a short synthetic fragment based on its actin-binding region. Think of thymosin beta-4 as the whole tool and TB-500 as the working tip.

Sellers sometimes use the two names as if they were identical. They overlap in mechanism, but they are different molecules. For the deeper protein biology, see the thymosin beta-4 guide.

What is TB-500 studied for?

TB-500 is studied mostly for recovery: helping soft tissue, muscle, and skin repair after strain or injury. Active adults look at it for the same reasons they look at other recovery peptides. The clearest signals in research are cell migration, blood-vessel growth, and inflammation balance.

• Muscle and soft-tissue recovery after hard training or a strain.
• Skin and wound repair, where thymosin beta-4 has the most animal data.
• Blood-vessel growth to support healing tissue.
• Flexibility and general recovery, often discussed alongside tendon and ligament work.

For how these uses map to specific injuries, see the best peptides for injury recovery and best peptides for tendon repair guides. Dose questions are covered in the TB-500 dosage guide.

How strong is the evidence for TB-500?

Thymosin beta-4 has a deep research history in animal models for wound healing, heart repair, and eye injury. TB-500, the fragment built around its actin-binding region, is studied for those same repair signals. Lab and animal work map how it acts on actin and helps cells migrate toward damaged tissue.

TB-500 does not yet have a cleared, regulated compounding pathway, and it is part of the FDA's July 2026 PCAC review. That is why the sound move is a licensed prescriber and an FDA-registered 503A pharmacy rather than a research-only vial with no prescriber or pharmacy behind it.

How is TB-500 different from BPC-157?

They are the two most-discussed recovery peptides, and they are studied as complements, not copies. TB-500 acts more body-wide through cell migration. BPC-157 is studied for more localized repair at the injury site, with strong signals for tendon, ligament, and gut tissue.

• TB-500: systemic signal, muscle and skin, actin and cell migration.
• BPC-157: localized repair, tendon and gut, blood-vessel growth at the site.
• Both: mostly animal evidence.

Because their mechanisms differ, some research protocols study them together. See the full BPC-157 vs. TB-500 comparison and the BPC-157 and TB-500 stack overview.

Is TB-500 safe, and what are the side effects?

Most of what is known about TB-500's side effects comes from user reports rather than completed human trials. Reported effects in user accounts tend to be mild and short: fatigue, head rush, or irritation at the injection site. Those are self-reports, not trial data, so they should be read with caution.

• Injection-site redness or irritation.
• Temporary tiredness or a head-rush feeling.
• Long-term human safety data is still being gathered.

The biggest safety variable is not the peptide itself. It is the source. A prescriber can screen for reasons TB-500 may not fit you, and a licensed pharmacy controls what is actually in the vial. More detail lives in the TB-500 side effects guide.

Where does TB-500 come from today, and what's the risk?

Right now, most TB-500 for sale is research-grade or grey-market. It is labeled "not for human use," it comes with no prescriber, and no licensed pharmacy stands behind it. That is the real risk: you cannot verify the dose, the purity, or what else is in the vial.

If you are researching where to buy, read TB-500 where to buy first so you understand what a legitimate path looks like versus a grey-market one.

How does pru handle TB-500?

pru is a telehealth platform for peptides. Licensed physicians prescribe, and FDA-regulated 503A pharmacies compound and fill. You pay about $50 a month for the membership, and any peptide is billed separately at cost, itemized, with no markup. You select what you want to explore, and the physician confirms whether it fits you.

TB-500 is on pru's roadmap, not a shortcut. On April 15, 2026, the FDA removed 12 peptides, including BPC-157 and TB-500, from the 503A "do not compound" Category 2 list. On July 23-24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) reviews seven of them, TB-500 among them, to weigh whether they can be compounded through 503A pharmacies. Removal from Category 2 is not the same as approval and not final clearance yet.

What is live today in this recovery lane is GHK-Cu cream, a copper peptide studied for skin and tissue support. You can browse the full repair and regeneration lane or see the pricing page to understand the at-cost model.

Taking recovery seriously and looking into your options ahead of an injury is a smart, responsible instinct, and pru exists to make the informed path the accessible one: licensed physicians, pharmacy-grade medicine, and at-cost pricing. Start with what is live today, and take the next step on TB-500 when the pathway opens.

Related reading

Keep going with the rest of the recovery-peptide library:

• TB-500 benefits
• TB-500 dosage
• BPC-157 vs. TB-500
• Thymosin beta-4 guide
• Best peptides for injury recovery
• GHK-Cu guide

Or browse the live catalog at pru shop.

Common questions